Akèy › Twoub depresif majè
Etid klinik pou Twoub depresif majè ap rekrite nan Etazini
156 etid pou Twoub depresif majè ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY37 etid
- Boston, MA30 etid
- Atlanta, GA24 etid
- Philadelphia, PA22 etid
- Orlando, FL19 etid
- Tampa, FL17 etid
- Miami, FL17 etid
- Chicago, IL16 etid
- Houston, TX16 etid
- San Diego, CA16 etid
- Little Rock, AR14 etid
- Austin, TX13 etid
- Orange, CA13 etid
- Glendale, CA12 etid
- Concord, CA12 etid
- Los Angeles, CA12 etid
- Las Vegas, NV12 etid
- Jacksonville, FL12 etid
- Cincinnati, OH11 etid
- Washington, DC11 etid
- Grand Prairie, TX10 etid
- Bellevue, WA9 etid
- Dallas, TX9 etid
- Newton, MA9 etid
- Oceanside, CA9 etid
- O'Fallon, MO9 etid
- Oklahoma City, OK9 etid
- Hartford, CT9 etid
- Brooklyn, NY9 etid
- San Francisco, CA8 etid
- San Bernardino, CA8 etid
- Hialeah, FL8 etid
- Columbus, OH8 etid
- Baltimore, MD8 etid
- Cleveland, OH8 etid
- Birmingham, AL8 etid
- Everett, WA8 etid
- Mountain View, CA7 etid
- Hollywood, FL7 etid
- Phoenix, AZ7 etid
Pa eta
- Alabama14 etid
- Arizona12 etid
- Arkansas15 etid
- Colorado10 etid
- Connecticut16 etid
- Distrik Columbia3 etid
- Florid31 etid
- Georgia32 etid
- Idaho3 etid
- Illinois19 etid
- Indiana4 etid
- Iowa5 etid
- Kalifòni51 etid
- Lwizyàn5 etid
- Maryland20 etid
- Massachusetts44 etid
- Michigan4 etid
- Minnesota7 etid
- Mississippi3 etid
- Missouri16 etid
- Nevada12 etid
- New Jersey10 etid
- New Mexico4 etid
- New York47 etid
- North Carolina12 etid
- Ohio29 etid
- Oklahoma12 etid
- Oregon5 etid
- Pennsylvania26 etid
- South Carolina8 etid
- Tennessee6 etid
- Texas37 etid
- Utah13 etid
- Virginia7 etid
- Washington20 etid
- Wisconsin3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Precision Depression Adalimumab Trial
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07845604Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium
Ap rekrite
Laj 22 a 85 · Tout sèks · Mizajou Sep 29, 2026 · NCT07594483Characterization and Treatment of Adolescent Depression
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 11 a 25 · Tout sèks · Mizajou Sep 28, 2026 · NCT03388606JAK Signaling in Depression
Ap rekriteFaz 2
Laj 25 a 55 · Tout sèks · Mizajou Sep 28, 2026 · NCT07003997Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Sep 25, 2026 · NCT06559306A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07621237A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Ap rekriteFaz 3
Laj 12 a 17 · Tout sèks · Mizajou Sep 25, 2026 · NCT07227454A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Ap rekriteFaz 3
Laj 18 a 85 · Tout sèks · Mizajou Sep 25, 2026 · NCT06793397Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 25, 2026 · NCT05850689Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 24, 2026 · NCT06830044DBS for TRD With the Medtronic Percept PC
Ap rekrite
Laj 25 a 70 · Tout sèks · Mizajou Sep 22, 2026 · NCT05773755Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Sep 22, 2026 · NCT03065335Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
Ap rekriteFaz 2Volontè an sante akeyi
Laj 8 a 65 · Tout sèks · Mizajou Sep 22, 2026 · NCT00018057The Medically Tailored Groceries and Mental Health Study
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07779707A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07105111Accelerated TMS for Perinatal Depression
Ap rekrite
Laj 18 a 55 · Fanm · Mizajou Sep 18, 2026 · NCT06968390Lumateperone for Late-Life Depression
Ap rekriteFaz 3
Laj 60 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07623135Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study
Ap rekrite
Laj 18 a 85 · Tout sèks · Mizajou Sep 15, 2026 · NCT07217223Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
Ap rekriteFaz 1Volontè an sante akeyi
Laj 21 a 45 · Tout sèks · Mizajou Sep 15, 2026 · NCT06480201Pattern Separation in Major Depressive Disorder
Ap rekriteFaz 1
Laj 18 a 50 · Tout sèks · Mizajou Sep 15, 2026 · NCT07139834A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Sep 14, 2026 · NCT07065240ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Sep 14, 2026 · NCT07284667Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Sep 14, 2026 · NCT06511908Leucine in Midlife Depression
Ap rekriteFaz 2
Laj 35 a 65 · Tout sèks · Mizajou Sep 11, 2026 · NCT06580145Defining Neurobiological Links Between Substance Use and Mental Illness
Ap rekriteVolontè an sante akeyi
Laj 18 a 60 · Tout sèks · Mizajou Sep 11, 2026 · NCT05538910Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.